Teva Pharmaceutical Industries Limited (TEVA) Financials
Key financial figures for Teva Pharmaceutical Industries Limited (Q2 2026).
Teva Pharmaceutical Industries Limited reported revenue of $4.14 billion for Q2 FY2026, down 0.8% from the same period a year earlier. The company posted a net loss of $576.0 million, or -$0.49 per share. Operating margin came to 3.6%, against 10.9% a year earlier. Free cash flow for the period was $307.0 million. Across the last 5 reported quarters, quarterly revenue has moved from $4.18 billion in Q2 FY2025 to $4.14 billion in Q2 FY2026. The figures above are as filed, and the full income statement, balance sheet and cash flow history for Teva Pharmaceutical Industries Limited are on the SentiSense financials page.
- Revenue
- $4.1B
- Net Income
- -$576M
- EPS
- $-0.49
- Total Assets
- $39.9B
- Operating Cash Flow
- $411M
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q2 FY2026 | $4.1B | -$576M | -$0.49 | 3.6% | $307M |
| Q1 FY2026 | $4.0B | $369M | $0.31 | 16.38% | -$208M |
| Q4 FY2025 | $4.7B | $480M | $0.41 | 6.37% | $1.0B |
| Q3 FY2025 | $4.5B | $433M | $0.37 | 19.69% | $233M |
| Q2 FY2025 | $4.2B | $282M | $0.24 | 10.9% | $131M |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2025 | $17.3B | $1.4B | $1.21 | 12.5% | $1.1B |
| FY2024 | $16.5B | -$1.6B | -$1.45 | -1.83% | $749M |
| FY2023 | $15.8B | -$559M | -$0.50 | 2.73% | $842M |
Frequently asked questions
What was Teva Pharmaceutical Industries Limited's revenue last quarter?
Teva Pharmaceutical Industries Limited reported revenue of $4.14 billion for Q2 FY2026, down 0.8% from the same period a year earlier.
Is Teva Pharmaceutical Industries Limited profitable?
Not in its most recent reported period. Teva Pharmaceutical Industries Limited reported a net loss of $576.0 million for Q2 FY2026, a net margin of -13.91% on revenue.
How has Teva Pharmaceutical Industries Limited's margin trended?
Operating margin was 3.6% in Q2 FY2026, compared with 10.9% in the same period a year earlier. The quarter by quarter series is on the SentiSense financials page.
How much free cash flow did Teva Pharmaceutical Industries Limited generate?
Teva Pharmaceutical Industries Limited generated free cash flow of $307.0 million in Q2 FY2026, after capital expenditure.
Full income statement, balance sheet and cash flow for Teva Pharmaceutical Industries Limited on SentiSense, with up to forty quarters and twenty fiscal years of history.